APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rare Neurodegenerative Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Rare Neurodegenerative Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025198 pages

Choose your research edition.

Industry ResearchRare Neurodegenerative Disease Treatment Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Rare Neurodegenerative Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Rare Neurodegenerative Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rare Neurodegenerative Disease Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Rare Neurodegenerative Disease Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Rare Neurodegenerative Disease Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Rare Neurodegenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rare Neurodegenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rare Neurodegenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Rare Neurodegenerative Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Rare Neurodegenerative Disease Treatment include Teva Pharmaceuticals, Sanofi, Johnson and Johnson, Novartis, Pfizer, GlaxoSmithKline, Bayer, Merck KGaA and Hoffmann-La Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rare Neurodegenerative Disease Treatment market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rare Neurodegenerative Disease Treatment and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rare Neurodegenerative Disease Treatment sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rare Neurodegenerative Disease Treatment market size, projected growth trends, production technologies, key applications, and end-use industries.

Rare Neurodegenerative Disease Treatment Segment by Company

Teva Pharmaceuticals

Sanofi

Johnson and Johnson

Novartis

Pfizer

GlaxoSmithKline

Bayer

Merck KGaA

Hoffmann-La Roche

Allergan

Rare Neurodegenerative Disease Treatment Segment by Type

Neuroprotective Agents

Neurotransmitter Agents

Biologics

Others

Rare Neurodegenerative Disease Treatment Segment by Application

Attention Deficit Hyperactivity Disorder (ADHD)

Parkinson’s Disease

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer’s Disease

Others

Rare Neurodegenerative Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Neurodegenerative Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rare Neurodegenerative Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Neurodegenerative Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rare Neurodegenerative Disease Treatment market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Rare Neurodegenerative Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Rare Neurodegenerative Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Rare Neurodegenerative Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Rare Neurodegenerative Disease Treatment Industry Trends Table 2. Rare Neurodegenerative Disease Treatment Industry Drivers Table 3. Rare Neurodegenerative Disease Treatment Industry Opportunities and Challenges Table 4. Rare Neurodegenerative Disease Treatment Industry Restraints Table 5. Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Rare Neurodegenerative Disease Treatment Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Manufacturers Table 9. Global Rare Neurodegenerative Disease Treatment Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Rare Neurodegenerative Disease Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Rare Neurodegenerative Disease Treatment Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Rare Neurodegenerative Disease Treatment Manufacturers, Product Type & Application Table 13. Global Rare Neurodegenerative Disease Treatment Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Rare Neurodegenerative Disease Treatment by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Neuroprotective Agents Table 17. Major Manufacturers of Neurotransmitter Agents Table 18. Major Manufacturers of Biologics Table 19. Major Manufacturers of Others Table 20. Global Rare Neurodegenerative Disease Treatment Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Rare Neurodegenerative Disease Treatment Sales by Type (2021-2026) & (K Units) Table 22. Global Rare Neurodegenerative Disease Treatment Sales by Type (2027-2032) & (K Units) Table 23. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2021-2026) Table 24. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2027-2032) Table 25. Global Rare Neurodegenerative Disease Treatment Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Rare Neurodegenerative Disease Treatment Revenue by Type (2021-2026) & (K Units) Table 27. Global Rare Neurodegenerative Disease Treatment Revenue by Type (2027-2032) & (K Units) Table 28. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Attention Deficit Hyperactivity Disorder (ADHD) Table 31. Major Manufacturers of Parkinson’s Disease Table 32. Major Manufacturers of Amyotrophic Lateral Sclerosis (ALS) Table 33. Major Manufacturers of Alzheimer’s Disease Table 34. Major Manufacturers of Others Table 35. Global Rare Neurodegenerative Disease Treatment Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Rare Neurodegenerative Disease Treatment Sales by Application (2021-2026) & (K Units) Table 37. Global Rare Neurodegenerative Disease Treatment Sales by Application (2027-2032) & (K Units) Table 38. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2021-2026) Table 39. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2027-2032) Table 40. Global Rare Neurodegenerative Disease Treatment Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Rare Neurodegenerative Disease Treatment Revenue by Application (2021-2026) & (K Units) Table 42. Global Rare Neurodegenerative Disease Treatment Revenue by Application (2027-2032) & (K Units) Table 43. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2021-2026) Table 44. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2027-2032) Table 45. Global Rare Neurodegenerative Disease Treatment Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Rare Neurodegenerative Disease Treatment Sales by Region (2021-2026) & (K Units) Table 47. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Region (2021-2026) Table 48. Global Rare Neurodegenerative Disease Treatment Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Rare Neurodegenerative Disease Treatment Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units) Table 52. North America Rare Neurodegenerative Disease Treatment Sales by Country (2027-2032) & (K Units) Table 53. Europe Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units) Table 55. Europe Rare Neurodegenerative Disease Treatment Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2027-2032) & (K Units) Table 62. Global Rare Neurodegenerative Disease Treatment Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Rare Neurodegenerative Disease Treatment Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Rare Neurodegenerative Disease Treatment Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Region (2021-2026) Table 66. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Region (2027-2032) Table 67. Teva Pharmaceuticals Company Information Table 68. Teva Pharmaceuticals Business Overview Table 69. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Portfolio Table 71. Teva Pharmaceuticals Recent Development Table 72. Sanofi Company Information Table 73. Sanofi Business Overview Table 74. Sanofi Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Sanofi Rare Neurodegenerative Disease Treatment Product Portfolio Table 76. Sanofi Recent Development Table 77. Johnson and Johnson Company Information Table 78. Johnson and Johnson Business Overview Table 79. Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Portfolio Table 81. Johnson and Johnson Recent Development Table 82. Novartis Company Information Table 83. Novartis Business Overview Table 84. Novartis Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novartis Rare Neurodegenerative Disease Treatment Product Portfolio Table 86. Novartis Recent Development Table 87. Pfizer Company Information Table 88. Pfizer Business Overview Table 89. Pfizer Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Pfizer Rare Neurodegenerative Disease Treatment Product Portfolio Table 91. Pfizer Recent Development Table 92. GlaxoSmithKline Company Information Table 93. GlaxoSmithKline Business Overview Table 94. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Portfolio Table 96. GlaxoSmithKline Recent Development Table 97. Bayer Company Information Table 98. Bayer Business Overview Table 99. Bayer Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Bayer Rare Neurodegenerative Disease Treatment Product Portfolio Table 101. Bayer Recent Development Table 102. Merck KGaA Company Information Table 103. Merck KGaA Business Overview Table 104. Merck KGaA Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Merck KGaA Rare Neurodegenerative Disease Treatment Product Portfolio Table 106. Merck KGaA Recent Development Table 107. Hoffmann-La Roche Company Information Table 108. Hoffmann-La Roche Business Overview Table 109. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Portfolio Table 111. Hoffmann-La Roche Recent Development Table 112. Allergan Company Information Table 113. Allergan Business Overview Table 114. Allergan Rare Neurodegenerative Disease Treatment Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Allergan Rare Neurodegenerative Disease Treatment Product Portfolio Table 116. Allergan Recent Development Table 117. Key Raw Materials Table 118. Raw Materials Key Suppliers Table 119. Rare Neurodegenerative Disease Treatment Distributors List Table 120. Rare Neurodegenerative Disease Treatment Customers List Table 121. Research Programs/Design for This Report Table 122. Authors List of This Report Table 123. Secondary Sources Table 124. Primary Sources List of Figures Figure 1. Rare Neurodegenerative Disease Treatment Product Image Figure 2. Global Rare Neurodegenerative Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rare Neurodegenerative Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Rare Neurodegenerative Disease Treatment Sales (2021-2032) & (K Units) Figure 5. Global Rare Neurodegenerative Disease Treatment Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Rare Neurodegenerative Disease Treatment Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Neuroprotective Agents Image Figure 9. Neurotransmitter Agents Image Figure 10. Biologics Image Figure 11. Others Image Figure 12. Global Rare Neurodegenerative Disease Treatment Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Rare Neurodegenerative Disease Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2021-2032) Figure 15. Global Rare Neurodegenerative Disease Treatment Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Rare Neurodegenerative Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2021-2032) Figure 18. Attention Deficit Hyperactivity Disorder (ADHD) Image Figure 19. Parkinson’s Disease Image Figure 20. Amyotrophic Lateral Sclerosis (ALS) Image Figure 21. Alzheimer’s Disease Image Figure 22. Others Image Figure 23. Global Rare Neurodegenerative Disease Treatment Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Rare Neurodegenerative Disease Treatment Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2021-2032) Figure 26. Global Rare Neurodegenerative Disease Treatment Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Rare Neurodegenerative Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2021-2032) Figure 29. North America Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2021-2032) Figure 31. U.S. Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2021-2032) Figure 36. Germany Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2021-2032) Figure 43. China Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Market Share by Country (2021-2032) Figure 51. Brazil Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Rare Neurodegenerative Disease Treatment Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Rare Neurodegenerative Disease Treatment Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Rare Neurodegenerative Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 62. North America Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Rare Neurodegenerative Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 64. Europe Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Rare Neurodegenerative Disease Treatment Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Rare Neurodegenerative Disease Treatment Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Neuroprotective Agents
  • Neurotransmitter Agents
  • Biologics
  • Others
Applications
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Parkinson’s Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Alzheimer’s Disease
  • Others
Companies covered
  • Teva Pharmaceuticals
  • Sanofi
  • Johnson and Johnson
  • Novartis
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • Merck KGaA
  • Hoffmann-La Roche
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rare Neurodegenerative Disease Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rare Neurodegenerative Disease Treatment Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Rare Neurodegenerative Disease Treatment Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Rare Neurodegenerative Disease Treatment Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Rare Neurodegenerative Disease Treatment Market Dynamics
  1. 2.1 Rare Neurodegenerative Disease Treatment Industry Trends
  2. 2.2 Rare Neurodegenerative Disease Treatment Industry Drivers
  3. 2.3 Rare Neurodegenerative Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Rare Neurodegenerative Disease Treatment Industry Restraints
3 Rare Neurodegenerative Disease Treatment Market by Manufacturers
  1. 3.1 Global Rare Neurodegenerative Disease Treatment Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Rare Neurodegenerative Disease Treatment Sales by Manufacturers (2021-2026)
  3. 3.3 Global Rare Neurodegenerative Disease Treatment Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Rare Neurodegenerative Disease Treatment Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Rare Neurodegenerative Disease Treatment Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Rare Neurodegenerative Disease Treatment Manufacturers, Product Type & Application
  7. 3.7 Global Rare Neurodegenerative Disease Treatment Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Rare Neurodegenerative Disease Treatment Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Rare Neurodegenerative Disease Treatment Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Rare Neurodegenerative Disease Treatment Tier 1, Tier 2, and Tier 3
4 Rare Neurodegenerative Disease Treatment Market by Type
  1. 4.1 Rare Neurodegenerative Disease Treatment Type Introduction
  2. 4.1.1 Neuroprotective Agents
  3. 4.1.2 Neurotransmitter Agents
  4. 4.1.3 Biologics
  5. 4.1.4 Others
  6. 4.2 Global Rare Neurodegenerative Disease Treatment Sales by Type
  7. 4.2.1 Global Rare Neurodegenerative Disease Treatment Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Rare Neurodegenerative Disease Treatment Sales by Type (2021-2032)
  9. 4.2.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Type (2021-2032)
  10. 4.3 Global Rare Neurodegenerative Disease Treatment Revenue by Type
  11. 4.3.1 Global Rare Neurodegenerative Disease Treatment Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Rare Neurodegenerative Disease Treatment Revenue by Type (2021-2032)
  13. 4.3.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Type (2021-2032)
5 Rare Neurodegenerative Disease Treatment Market by Application
  1. 5.1 Rare Neurodegenerative Disease Treatment Application Introduction
  2. 5.1.1 Attention Deficit Hyperactivity Disorder (ADHD)
  3. 5.1.2 Parkinson’s Disease
  4. 5.1.3 Amyotrophic Lateral Sclerosis (ALS)
  5. 5.1.4 Alzheimer’s Disease
  6. 5.1.5 Others
  7. 5.2 Global Rare Neurodegenerative Disease Treatment Sales by Application
  8. 5.2.1 Global Rare Neurodegenerative Disease Treatment Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Rare Neurodegenerative Disease Treatment Sales by Application (2021-2032)
  10. 5.2.3 Global Rare Neurodegenerative Disease Treatment Sales Market Share by Application (2021-2032)
  11. 5.3 Global Rare Neurodegenerative Disease Treatment Revenue by Application
  12. 5.3.1 Global Rare Neurodegenerative Disease Treatment Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Rare Neurodegenerative Disease Treatment Revenue by Application (2021-2032)
  14. 5.3.3 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Application (2021-2032)
6 Global Rare Neurodegenerative Disease Treatment Sales by Region
  1. 6.1 Global Rare Neurodegenerative Disease Treatment Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rare Neurodegenerative Disease Treatment Sales by Region (2021-2032)
  3. 6.2.1 Global Rare Neurodegenerative Disease Treatment Sales by Region (2021-2026)
  4. 6.2.2 Global Rare Neurodegenerative Disease Treatment Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Rare Neurodegenerative Disease Treatment Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Rare Neurodegenerative Disease Treatment Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Rare Neurodegenerative Disease Treatment Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Rare Neurodegenerative Disease Treatment Revenue by Region
  1. 7.1 Global Rare Neurodegenerative Disease Treatment Revenue by Region
  2. 7.1.1 Global Rare Neurodegenerative Disease Treatment Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2021-2026)
  4. 7.1.3 Global Rare Neurodegenerative Disease Treatment Revenue by Region (2027-2032)
  5. 7.1.4 Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Rare Neurodegenerative Disease Treatment Revenue (2021-2032)
  8. 7.2.2 North America Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Rare Neurodegenerative Disease Treatment Revenue (2021-2032)
  11. 7.3.2 Europe Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Rare Neurodegenerative Disease Treatment Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Rare Neurodegenerative Disease Treatment Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson and Johnson
  14. 8.3.1 Johnson and Johnson Company Information
  15. 8.3.2 Johnson and Johnson Business Overview
  16. 8.3.3 Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Portfolio
  18. 8.3.5 Johnson and Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Rare Neurodegenerative Disease Treatment Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Rare Neurodegenerative Disease Treatment Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Rare Neurodegenerative Disease Treatment Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 Merck KGaA
  44. 8.8.1 Merck KGaA Company Information
  45. 8.8.2 Merck KGaA Business Overview
  46. 8.8.3 Merck KGaA Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck KGaA Rare Neurodegenerative Disease Treatment Product Portfolio
  48. 8.8.5 Merck KGaA Recent Developments
  49. 8.9 Hoffmann-La Roche
  50. 8.9.1 Hoffmann-La Roche Company Information
  51. 8.9.2 Hoffmann-La Roche Business Overview
  52. 8.9.3 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Portfolio
  54. 8.9.5 Hoffmann-La Roche Recent Developments
  55. 8.10 Allergan
  56. 8.10.1 Allergan Company Information
  57. 8.10.2 Allergan Business Overview
  58. 8.10.3 Allergan Rare Neurodegenerative Disease Treatment Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Allergan Rare Neurodegenerative Disease Treatment Product Portfolio
  60. 8.10.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rare Neurodegenerative Disease Treatment Value Chain Analysis
  2. 9.1.1 Rare Neurodegenerative Disease Treatment Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rare Neurodegenerative Disease Treatment Production Mode & Process
  6. 9.2 Rare Neurodegenerative Disease Treatment Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rare Neurodegenerative Disease Treatment Distributors
  9. 9.2.3 Rare Neurodegenerative Disease Treatment Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst